Loading...

Australia’s Deadliest Women’s Cancer: Why Women Need Urgent Action Now

Ovarian cancer is now confirmed as the deadliest women’s cancer, with the latest statistics revealing a five-year survival rate of just 49%. Tragically, two-thirds (67%) of cases are diagnosed at an advanced stage, where survival drops to just 29%1.  [...]

Australia’s Deadliest Women’s Cancer: Why Women Need Urgent Action Now2025-04-11T13:55:30+10:00

ANZGOG Announces Keynote Speaker for 2025 Annual Scientific Meeting: A/Professor Carien Creutzberg

The Australia New Zealand Gynaecological Oncology Group (ANZGOG) is pleased to welcome internationally renowned Radiation Oncologist Professor Carien Creutzberg as a keynote speaker at the 2024 ANZGOG Annual Scientific Meeting (ASM), taking place in Canberra from 5-7 March 2025.  [...]

ANZGOG Announces Keynote Speaker for 2025 Annual Scientific Meeting: A/Professor Carien Creutzberg2025-02-05T12:40:54+11:00

ANZGOG Announces Keynote Speaker for 2025 Annual Scientific Meeting: A/Professor David Tan

The Australia New Zealand Gynaecological Oncology Group (ANZGOG) is pleased to announce that Associate Professor David Tan, a leading medical oncologist and clinician scientist from Singapore, will be one of the International Keynote speakers at the upcoming ANZGOG Annual [...]

ANZGOG Announces Keynote Speaker for 2025 Annual Scientific Meeting: A/Professor David Tan2025-02-24T19:28:40+11:00

ANZGOG welcomes the Australian Government’s support to accelerate gynaecological cancer clinical trials.

  The Australia New Zealand Gynaecological Oncology Group (ANZGOG) is thrilled to announce it has been awarded $1.58 million over three years (2024-2027) as part of the Australian Government’s $22.19 million investment in cancer clinical trials through the Support [...]

ANZGOG welcomes the Australian Government’s support to accelerate gynaecological cancer clinical trials.2024-11-08T15:22:31+11:00

RAMP 301 trial investigates treatment for a rare subtype of ovarian cancer – low grade serous ovarian cancer

RAMP 301 (VS-6766-301/GOG-3097/ENGOT-ov81) is a Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator’s Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC). We’re excited to announce [...]

RAMP 301 trial investigates treatment for a rare subtype of ovarian cancer – low grade serous ovarian cancer2024-12-12T09:56:45+11:00

The Future of Gynaecological Cancer Care: A Conversation with ANZGOG’s Alison Davis

As part of ANZGOG’s #GynaeCancerMatters campaign for Gynaecological Cancer Awareness Month, we are pleased to feature an insightful interview with Associate Professor Alison Davis. Assoc Prof Alison Davis, Medical Oncologist (ACT) With over 20 years [...]

The Future of Gynaecological Cancer Care: A Conversation with ANZGOG’s Alison Davis2024-09-11T15:46:06+10:00

Recognising Diverse Needs during NAIDOC Week: Tracy’s Journey with Gynaecological Cancer

During National Aboriginal and Islanders Day Observance Committee (NAIDOC) Week, we celebrate Tracy's journey. Tracy, a proud Aboriginal woman, embodies determination and leadership. She has always been a go-getter. Unlike many in her community, she is [...]

Recognising Diverse Needs during NAIDOC Week: Tracy’s Journey with Gynaecological Cancer2024-07-09T15:54:47+10:00
Go to Top